PerkinElmer spooked into lowering full-year earnings forecast
This article was originally published in Clinica
Executive Summary
PerkinElmer’s third quarter results came in slightly above analysts’ expectations, with its profit boosted by a lower tax rate, according to Jefferies’ Brandon Couillard. However, this did not stop the company narrowing its adjusted earnings guidance for full-year 2013 to $2.04-2.07 per share, the lower end of its previous range of $2.03-2.10. The firm had already lowered its EPS prediction from $2.24-2.32 earlier this year (www.clinica.co.uk, 29 April 2013). Full-year revenue guidance is unchanged, with low-single-digit organic growth anticipated.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.